We would love to hear your thoughts about our site and services, please take our survey here.
Wishful thinking but I want it to be a number of car manufacturers telling GR you keep your beloved Zulu and we will give you X amount to get the lithium out but we want Y amount of it before anyone else gets their hands on it.
"Subsequent to the awarding of the EPO for Zulu, Premier has received multiple approaches both proposing direct funding for the Zulu DFS as well as investment linked to product take off and future mine development. Premier is evaluating these and now expects to be able to update our shareholders on the way forward by the end of this month."
Forget vivid for a second just read this...
Paraytec's team has demonstrated that its patented capture and detection technology platform works with a range of aptamers and proteins. With this knowledge, the platform will be developed to test for new viruses and variants of COVID-19. Importantly, the Paraytec team is also exploring its use for rapid detection and identification of bacterial and viral pathogens present in patients with sepsis, a global killer of over 11 million people per year.
Evaluation of LamPORE rapid tests for Covid-19 show high levels of diagnostic sensitivityThe evaluation of the novel diagnostic platform for detecting SARS-CoV-2RNA was conducted by a team of scientists, including researchers from the University of SheffieldThe new technology has the potential to analyse thousands of samples per day on a single instrumentPreliminary results suggest high levels of diagnostic sensitivity in the new testing platform, which could mean an expansion to the scale of testing offered in the future to help control the pandemic.
A team of scientists, including researchers from the University of Sheffield, have today (25 September 2020) published their evaluation of a rapid, new Covid-19 testing technology, which has the potential to expand the type and scale of testing available.
LamPORE, a novel diagnostic platform for detecting SARS-CoV-2RNA, combines loop-mediated isothermal amplification with nanopore sequencing, meaning it has the potential to analyse thousands of samples per day on a single instrument.
Although preliminary, the results suggest high levels of diagnostic sensitivity in LamPORE which could mean an expansion to the scale of testing that could be offered in the future to help control the SARS-CoV-2 pandemic.
The collaboration between the University of Sheffield and colleagues at Public Health England Porton Down (PHE), Sheffield Teaching Hospitals NHS Foundation Trust and the University of Oxford, including support from the NIHR Oxford Biomedical Research Centre, evaluated the performance of LamPORE against RT-PCR - the most commonly-used laboratory test for Covid-19.
These are preliminary but promising data that suggest LamPORE has the potential to expand the type and scale of SARS-CoV-2 testing that could be offered in the future.
DR THUSHAN DE SILVA, UNIVERSITY OF SHEFFIELD
The team used RNA (Ribonucleic acid which is a polymeric molecule essential in various biological roles in coding, decoding, regulation and expression of genes) extracted from two types of samples. Initially, mock samples formed of saliva from people without infection that had a known quantity of virus added to it, and subsequently nose and throat swabs from real Covid-19 patients collected during routine care at two UK hospitals - Oxford University Hospitals NHS Foundation Trust and Sheffield Teaching Hospitals NHS Foundation Trust.
The positive clinical specimens came mostly from patients with symptomatic infection, and among these LamPORE had a diagnostic sensitivity of 99.1 per cent (i.e. it was positive in 226 of 228 samples positive by RT-PCR).
Among negative clinical specimens, including 153 with other respiratory pathogens detected, LamPORE had a diagnostic specificity of 99.6 per cent (i.e. it was negative in 278 of 279
samples negative by RT-PCR). Overall, 1.4 per cent of samples produced an indeterminate result on first testing, and repeat LamPORE testing on the same RNA extract had a reproducib
Paraytec - Sheffield University - Portion Down....join the dots.
https://www.sheffield.ac.uk/news/nr/evaluation-of-lampore-rapid-covid-test-1.914302
https://www.gminsights.com/industry-analysis/marine-engines-market
www.marineinsight.com/main-engine/the-most-popular-marine-propulsion-engines-in-the-shipping-industry/
https://www.fortunebusinessinsights.com/industry-reports/marine-engine-market-100771
Was the POC for the same engines MSC is using not done for maersk and LONO not obtained? If yes then why does the LONO need to be obtained again?
https://www.aquafuelresearch.com/news-blog/formula-es-emission-free-charging
"Aquafuel is the industry partner currently testing bioMSAR® on a standard Cummins diesel generator owned by Quadrise at Aquafuel's UK test facility. The testing, first announced on 15 December 2020, is expected to be completed shortly with final report on the outcome expected in January 2021. bioMSAR® is a low carbon alternative to heavy fuel oil that combines renewable glycerine with MSAR® fuel technology to reduce CO2 emissions by 20-30%, as well as NOx and particulates."
If there are no delays we should get an update soon.
Oil to water was Desire Petroleum, Rockhopper made the sea lion discovery.. remember those days well